Business
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies.
About this update from Nutra Pharma Corp.
[{"type":"text","content":"\n \n \n Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies\n \n \nNutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies\n \n CORAL SPRINGS, FL--(Marketwired - May 31, 2017) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration today with the University of Maryland Bioprocess Scale-Up Facility (BSF) to optimize manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis.\n \"Pediatric Multiple Sclerosis is a pressing and unmet medical need,\" stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. \"These children have no therapeutic options that have been proven to be safe and effective for their disease. They must rely on off-label use of adult MS drugs,\" he continued. \"We have been laying the groundwork to move into sanctioned trials ever since we received Orphan Designation for RPI-78M. Standardizing and scaling up drug production with BSF is the next logical step,\" he concluded.\n The company previously announced that they had been granted an Orphan Designation from the US-FDA (Food and Drug Administration) for the treatment of Pediatric Multiple Sclerosis with RPI-78M. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.\n \"Based on our pre-clinical and open-label clinical studies, we believe that RPI-78M has the ability to successfully navigate the FDA approval process,\" commented Dale Vander Putten, PhD, Nutra Pharma's Chief Scientific Officer. \"We believe that a recombinant product will ultimately provide these kids with the best possible drug. We are now working with the BSF to scale up drug manufacturing in preparation for the upcoming Phase II clinical trials,\" he concluded.\n The BSF will utilize the cloned alpha-cobratoxin gene as the raw material for the production of the recombina...